Clinical effect of transarterial chemoembolization with ultra-liquid iodized oil combined with drug-eluting beads in treatment of Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma

Tang HaoHuan; Zhu XiaoLi; Wang WanSheng; Li WanCi; Zhou LinFeng; Du Hang

doi:10.3969/j.issn.1001-5256.2019.07.018

Volume 35 Issue 7

Jul. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(7): 1509-1513

PDF( 2060 KB)

Clinical effect of transarterial chemoembolization with ultra-liquid iodized oil combined with drug-eluting beads in treatment of Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2019.07.018

Department of Interventional Radiology, The First Affiliated Hospital of Soochow University

Research funding:

Received Date: 2019-02-01
Published Date: 2019-07-20

Abstract

Abstract

Objective To investigate the clinical effect and safety of transarterial chemoembolization ( TACE) with ultra-liquid iodized oil combined with drug-eluting beads in the treatment of Barcelona Clinic Liver Cancer ( BCLC) stage B/C hepatocellular carcinoma ( HCC) .Methods A retrospective analysis was performed for the clinical data of 51 patients with BCLC stage B/C HCC who underwent TACE with ultra-liquid iodized oil combined with drug-eluting beads in The First Affiliated Hospital of Soochow University from May 2016 to September 2018. Liver function was observed before treatment and at 3 days, 7 days, and 1 month after treatment, and adverse events and complications were recorded in detail. Modified Response Evaluation Criteria in Solid Tumors was used to evaluate clinical outcome at 1 and 3 months after surgery. The t-test was used for comparison of continuous data between two groups. Results Superselective TACE procedure was completed in all 51 patients. At 1 month after surgery, the target lesions had a disease remission rate of 70. 6% and a disease control rate of 96. 1%, while at 3 months after surgery, the target lesions had a disease remission rate of 64. 0% and a disease control rate of88. 0%. Of all 51 patients, 5 ( 9. 8%) experienced acute liver injury at 3 days after surgery, and there were significant changes in alanine aminotransferase ( ALT) , aspartate aminotransferase, total bilirubin ( TBil) , and albumin ( Alb) ( t =-5. 454, -3. 997, -5. 346, and7. 212, all P < 0. 001) . There were also significant changes in ALT, TBil, and Alb at 7 days after surgery ( t =-3. 177, -3. 665, and3. 194, all P < 0. 05) . Of all 51 patients, 35 ( 68. 6%) experienced grade 1 or 2 adverse events at 1 month after surgery, and no complications of liver failure, liver abscess, bile tumor, and gastrointestinal bleeding were observed. One patient died of multiple organ failure due to tumor progression on day 61 after surgery. Conclusion TACE with ultra-liquid iodized oil combined with drug-eluting beads is safe and effective in the treatment of BCLC stage B/C HCC, and further studies are needed to observe long-term efficacy and survival benefit.
- carcinoma, hepatocellular,
- iodized oil,
- microspheres,
- chemoembolization, therapeutic

FullText(HTML)

References(22)

References

[1]KAN Z, MADOFF DC.Liver anatomy:Microcirculation of the liver[J].Semin Intervent Radiol, 2008, 25 (2) :77-85.

[2]LEWIS AL, GONZALEZ MV, LEPPARD SW, et al.Doxorubicin eluting beads-1:Effects of drug loading on bead characteristics and drug distribution[J].J Mater Sci Mater Med, 2007, 18 (9) :1691-1699.

[3]LEWIS AL, GONZALEZ MV, LLOYD AW, et al.DC bead:In vitro characterization of a drug-delivery device for transarterial chemoembolization[J].J Vase Interv Radiol, 2006, 17 (2 Pt1) :335-342.

[4]National Health and Family Planning Commission of the People's Republic of China.Diagnosis, management, andtreatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.

[5] DUFOUR DR, LOTT JA, NOLTE FS, et al.Diagnosis and monitoring of hepatic injury, I.Performance characteristics of laboratory tests[J].Clin Chem, 2000, 46 (12) :2027-2049.

[6]LAMMER J, MALAGARI K, VOGL T, et al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma:Results of the PRE-CISION V study[J].Cardiovasc Intervent Radiol, 2010, 33 (1) :41-52.

[7] RISSE JH, MENZEL C, GRYNWALD F, et al.Therapy of hepatocellular cancer with iodine-131-Lipiodol[J].Rom J Gastroenterol, 2004, 13 (2) :119-124.

[8]LI SY, WU S, CHEN TS, et al.Effect of portal venous perfusion cinobufacini injection combined with TACE in patients with intermediate hepatocellular carcinoma[J].Clin J Med Offic, 2017, 45 (9) :884-886. (in Chinese) 李淑英, 吴申, 陈挺松, 等.经导管肝动脉栓塞化疗联合华蟾素门静脉灌注治疗中期原发性肝癌疗效研究[J].临床军医杂志, 2017, 45 (9) :884-846.

[9] HIGASHIHARA H.Transcatheter arterial chemoembolization of hepatocellular carcinoma:A Japanese experience[J].Hepatogastroenterology, 2002, 49 (43) :72-78.

[10] de BAERE T, DUFAUX J, ROCHE A, et al.Circulatory alterations inducedby intra-arterial injection of iodized oil and emulsions of iodized oiland doxorubicin:experimental study[J].Radiology, 1995, 194 (1) :165-70.

[11]KAN Z, IVANCEV K, HAGERSTRAND I, et al.In vivo microscopy of the liverafter injection of Lipiodol into the hepatic artery and portal vein inthe rat[J].Acta Radiologica, 1989, 30 (4) :419-425.

[12]ZHAO BL, CUI XJ, XING H, et al.Clinical effect of transcatheter arterial chemoembolization with iodinated oil combined with microspheres in treatment of large hepatocellular carcinoma[J].Shandong Med J, 2018, 58 (22) :87-89. (in Chinese) 赵邦利, 崔新江, 邢辉, 等.碘化油联合微球经导管肝动脉化疗栓塞治疗大肝癌效果观察[J].山东医药, 2018, 58 (22) :87-89.

[13]LUO JJ, YAN ZP, WANG JH, et al.HCC embolized by microspheres and iodized oil compared with by iodized oil alone[J].Chin Comput Med Imag, 2008, 14 (2) :154-159. (in Chinese) 罗剑钧, 颜志平, 王建华, 等.微球+碘化油联合栓塞与碘化油单独栓塞治疗肝癌的比较研究[J].中国医学计算机成像杂志, 2008, 14 (2) :154-159.

[14]ZHANG JX, LI FZ, CHAI J, et al.Clinical and controlled trial of transcatheter arterial chemoembolization with polyvinyl alcohol particle in patients with advanced hepatocellular carcinoma[J].J Hepatopancreatobiliary Surg, 2014, 26 (3) :195-197, 203. (in Chinese) 张军喜, 李发中, 柴健, 等.微球加碘化油栓塞治疗肝癌疗效的临床对照研究[J].肝胆胰外科杂志, 2014, 26 (3) :195-197, 203.

[15]YOU JX, WANG JB, AI ST, et al.TACE by using microspheres and lipiodol for the treatment of hepatocellular carcinoma:Analysis of short-term efficacy[J].J Intervent Radiol, 2017, 26 (6) :531-534. (in Chinese) 游建雄, 王精兵, 艾松涛, 等.微球联合碘油栓塞治疗肝癌的近期疗效分析[J].介入放射学杂志, 2017, 26 (6) :531-534.

[16]NAKAO N, UCHIDA H, KAMINO K, et al.Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis[J].Cardiovasc Intervent Radiol, 1994, 17 (2) :76-80.

[17]XIAO CJ, ZHENG LY.Clinical effect of transarterial chemoembolization in treatment of liver injury:An analysis of 100 cases[J].Chin J Radiol, 1997, 31 (11) :777-779. (in Chinese) 肖承江, 郑丽吟.肝动脉栓塞化疗对肝损害的观察 (附100例分析) [J].中华放射学杂志, 1997, 31 (11) :777-779.

[18] DUFOUR DR, LOTT JA, NOLTE FS, et al.Diagnosis and monitoring of hepatic injury.I.Performance characteristics of laboratory tests[J].Clin Chem, 2000, 46 (12) :2027-2049.

[19]KAN XF, ZHENG CS, XIONG B, et al.Simple conventional hepatic artery chemoembolization for the treatment of Barcelona stage C liver cancer:A clinic analysis[J].J Intervent Radiol, 2018, 27 (12) :1182-1185. (in Chinese) 阚雪锋, 郑传胜, 熊斌, 等.单纯经典肝动脉化疗栓塞术治疗巴塞罗那C期肝癌的临床分析[J].介入放射学杂志, 2018, 27 (12) :1182-1185.

[20]WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:The major impact of China[J].Hepatology, 2014, 60 (6) :2099-2108.

[21]ZHANG MY, NIU JQ.Prevalence of primary liver cancer in Eastern countries and related influencing factors[J].J Clin Hepatol, 2018, 34 (7) :1399-1402. (in Chinese) 张明媛, 牛俊奇.东方国家原发性肝癌发病趋势及影响因素[J].临床肝胆病杂志, 2018, 34 (7) :1399-1402.

[22]CAO K, BAO ZM, ZHOU XY, et al.Effects and mechanisms of hepatitis B virus X protein on invasion and migration of hepatocellular carcinoma cells[J].Chin J Dig Surg, 2017, 16 (2) :177-182. (in Chinese) 曹宽, 鲍仲明, 周新宇, 等.乙型肝炎病毒X蛋白对肝癌细胞侵袭与迁移能力的作用及机制[J].中华消化外科杂志, 2017, 16 (2) :177-182.

Relative Articles

[1]	Jun GAO, Huan CHEN, Yan LIU, Feng ZHANG, Yuzheng ZHUGE. Effect of interleukin-22 on hepatic stellate cell activation and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(11): 2229-2237. doi: 10.12449/JCH241116
[2]	Yekai ZONG, Jiangkai LIU. The physiological and pathological role of amyloid protein in the liver[J]. Journal of Clinical Hepatology, 2023, 39(11): 2730-2737. doi: 10.3969/j.issn.1001-5256.2023.11.031
[3]	Feiyan LI, Minggang WANG, Dewen MAO, Xiongbin GUI. Role of gasdermin D in the pathological progression of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(3): 707-712. doi: 10.3969/j.issn.1001-5256.2023.03.035
[4]	Xiaolu ZHAO, Chunyan ZHANG, Xiaoyang GAO, Yuehong MA. Mechanism of action of the Hippo/YAP pathway in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1654-1657. doi: 10.3969/j.issn.1001-5256.2022.07.037
[5]	Xin LUO, Ying QU, Xiaobo CAI, Lungen LU. Effects of antiviral therapy on the reversal of liver fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(11): 2596-2598. doi: 10.3969/j.issn.1001-5256.2022.11.032
[6]	Wenzheng YOU, Wanlei REN, Shiying XUAN, Doudou HU. Association between intrahepatic bile duct alterations and liver fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(1): 187-190. doi: 10.3969/j.issn.1001-5256.2022.01.032
[7]	Fan Chang, Wu FuRong, Zhang JiaFu, Jiang Hui. Role of pyroptosis in the pathogenesis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(5): 1138-1140. doi: 10.3969/j.issn.1001-5256.2020.05.042
[8]	YANG Jing, GAO Hong, ZHAO YaoWei, WANG Rui. Role of liver sinusoidal endothelial cells in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2601-2605. doi: 10.3969/j.issn.1001-5256.2020.11.046
[9]	Geng WenJing, Liu Hui, Ding HuiGuo. Recent advances in drug-induced liver injury: Potential mechanisms, pathological features, and biomarkers[J]. Journal of Clinical Hepatology, 2019, 35(4): 925-929. doi: 10.3969/j.issn.1001-5256.2019.04.049
[10]	Jiang LiNa, Zhao JingMin. A clinical trial on the follow-up of nonalcoholic fatty liver disease: An evaluation of pathological endpoint[J]. Journal of Clinical Hepatology, 2018, 34(12): 2505-2508. doi: 10.3969/j.issn.1001-5256.2018.12.004
[11]	Pan Jing, Pan WenTing, Wu LiHui. Expression and significance of Th22 cells and its functional factor interleukin-22 in mice with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1745-1749. doi: 10.3969/j.issn.1001-5256.2018.08.030
[12]	Wang BingQiong, Sun YaMeng, You Hong, Shao Chen, Wang TaiLing. Pathological assessment of liver fibrosis regression[J]. Journal of Clinical Hepatology, 2017, 33(3): 435-437. doi: 10.3969/j.issn.1001-5256.2017.03.007
[13]	Bao SuXia, Zheng JianMing, Shi GuangFeng. Research progress in association between interleukin-23 and liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(2): 393-396. doi: 10.3969/j.issn.1001-5256.2016.02.044
[14]	Wang Wei, Zhao RongRong, Yang XiaoFei, Huang ZhangXing, Lian JianQi, Wang JiuPing, Zhang Ye. Influence of Notch signaling pathway on interleukin-22 secreted by CD4~+T cells in patients with hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1315-1318. doi: 10.3969/j.issn.1001-5256.2016.07.020
[15]	Wu Qin, Meng FanPing, Ma XueMei, Jin Bo, Shen LiJun, Wu LiBing, Chu JinDong, Lai WenHui, Han JingJing, Li HanWei. Analysis of association between different HCV genotypes and serum interleukin-17, interleukin-6, and vitamin D in patients with HCV-related cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1849-1852. doi: 10.3969/j.issn.1001-5256.2015.11.019
[16]	Guan HaiTao, Zhao JinLi, Tang Rui, Sun LinLin. IL-17 promotes expression of fibrosis-related factors in hepatic stellate cells[J]. Journal of Clinical Hepatology, 2013, 29(5): 370-374.
[17]	Wang WeiBin, Zhu YouFu. A brief discussion on pathogenesis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(11): 805-809. doi: 10.3969/j.issn.1001-5256.2013.11.002
[18]	Sha XiuJuan, Xin GuiJie, Jin MeiShan, Chi TouMei, Niu JunQi. Pay much attention to the clinical application of pathological examination of liver biopsy in the diagnosis and treatment of liver disease[J]. Journal of Clinical Hepatology, 2012, 28(3): 223-226.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	翟飞，闫菊，何嘉宾，张庆勇，吴燕. 开腹联合肝脏离断和门静脉结扎二步肝切除术治疗原发性肝癌疗效及对患者肝功能指标、术后生存情况的影响. 临床和实验医学杂志. 2023(04): 375-379 .
2.	尚敏杰，张军港，顾宗庭，魏芳强，陶然，吴国清，文阳，沈坚，唐雨琪. 免疫联合靶向治疗预防肝细胞癌行ALPPS术后复发的临床疗效. 中华消化外科杂志. 2023(02): 281-285 .
3.	郭佳胤，徐杰，刘作金. 腹腔镜下ALPPS右半肝切除一例（附视频）. 中华肝脏外科手术学电子杂志. 2023(03): 345-347 .
4.	杨雄威，高晓杰，覃日利，张新晨. ALPPS临床应用及术式改良. 中华肝脏外科手术学电子杂志. 2022(04): 347-350 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1620) PDF downloads(288)

Clinical effect of transarterial chemoembolization with ultra-liquid iodized oil combined with drug-eluting beads in treatment of Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2019.07.018